Cargando…
Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria
BACKGROUND: The World Health Organization (WHO) recommends artemisinin‐based combination therapies (ACTs) to treat uncomplicated Plasmodium falciparum malaria. Concerns about artemisinin resistance have led to global initiatives to develop new partner drugs to protect artemisinin derivatives in ACT....
Autores principales: | Pryce, Joseph, Taylor, Melissa, Fox, Tilly, Hine, Paul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209011/ https://www.ncbi.nlm.nih.gov/pubmed/35726133 http://dx.doi.org/10.1002/14651858.CD006404.pub4 |
Ejemplares similares
-
Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria
por: Pryce, Joseph, et al.
Publicado: (2019) -
Artesunate plus pyronaridine for treating uncomplicated Plasmodium falciparum malaria
por: Bukirwa, Hasifa, et al.
Publicado: (2014) -
Efficacy and Safety of Pyronaridine–Artesunate for the Treatment of Uncomplicated Plasmodium falciparum and Plasmodium vivax Malaria in Myanmar
por: Han, Kay Thwe, et al.
Publicado: (2020) -
Efficacy and safety of pyronaridine-artesunate (Pyramax(®)) for the treatment of uncomplicated Plasmodium vivax malaria in Northwest Ethiopia
por: Mohammed, Hussein, et al.
Publicado: (2022) -
Pyronaridine–artesunate and artemether–lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a randomized controlled non-inferiority trial
por: Roth, Johanna M., et al.
Publicado: (2018)